A recent article published in The Wall Street Journal has said that pharmaceutical manufacturers Merck & Co. and Schering-Plough Corp. kept a study of their drug Vytorin under wraps for over a year due to data concerns. The article went on to say that the study, which found Vytorin was no better than a generic, has renewed concern over the practice of selective publication.
According to research from pharmaceutical research firm Best Practices, LLC, US, as the debate continues over how pharma companies manage the scientific publications process, organisations are adjusting their publication operations. Further, the study states that some companies have shifted their global publications functions out of commercial and into medical operations.
The study, 'Scientific Publications Strategy: Managing Reputation, Clinical Trial Results', illustrates how pharmaceutical companies are following a publishing strategy that presents all study findings while still driving brand strength through commercially relevant publications. Publishing executives of pharma and biotech companies can expect to use the research to evaluate the resources and strategies of their publication operations.
The study is available in the Best Practice Database, an online resource that contains more than $35 million in proprietary research conducted on behalf of executives from Fortune 500 companies. A complimentary excerpt of the publications study is available at http://www.best-in-class.com/dr292.htm.
More News in this Theme